NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

Is that true senti? I thought (or maybe hoped is the better word) that we had plenty of control arms from various tests out there that did separate. That is disappointing if there isn't a good control arm with this separated

If that is the case it sounds like the redefinition of GBM might have the effect of slightly lowering the potential market of dcvax-l and also not offering any improvement on the data (although there would be if we had a good contol arm). The benefit would be seen by the patient with the knowledge gained in what treatment(s) work for which patient.